Expression of glioma stem cell marker CD133 and O6- methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1305-1313

  He, Jie ^a,c   Shan, Zhengnan ^b   Li, Lihua ^c   Liu, Fen ^c   Liu, Zhihui ^c   Song, Mingxu ^c   Zhu, Haiqing ^d  

^a SOOCHOW UNIVERSITY   (China)

^b Shenzhen Research Institute of City University of Hong Kong ^*  (Hong Kong)

^c Department of Internal Oncology   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Glioma stem cells; Radiotherapy; Resistance; siRNA

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SMALL INTERFERING RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE SILENCING; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MGMT GENE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 80053133738     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1393     Document Type: Article

References (35)

1. Pegg AE: Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462: 83-100, 2000.
2. Coulondre C and Miller JH: Genetic studies of the lac repressor. IV. Mutagenic specificity in the lacI gene of Escherichia coli. J Mol Biol 117: 577-606, 1977. (Pubitemid 8256693)
3. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.
4. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004. (Pubitemid 38121035)
5. Salmaggi A, Boiardi A, Gelati M, et al: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54: 850-860, 2006. (Pubitemid 44671990)
6. Beier D, Röhrl S, Pillai DR, et al: Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68: 5706-5715, 2008.
7. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
8. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004. (Pubitemid 38375541)
9. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
10. + cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
11. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-340, 2004.
12. Yuan X, Curtin J, Xiong Y, et al: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392-9400, 2004. (Pubitemid 40069671)
13. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
14. Hemmati HD, Nakano I, Lazareff JA, et al: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183, 2003. (Pubitemid 37518036)
15. Wang J, Sakariassen PØ, Tsinkalovsky O, et al: CD133-negative glioma cells form tumors in nude rats and give rise to CD133- positive cells. Int J Cancer 122: 761-768, 2008.
16. Beier D, Hau P, Proescholdt M, et al: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015, 2007. (Pubitemid 46815044)
17. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005. (Pubitemid 40488633)
18. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemo- radiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
19. Singh SK, Clarke ID, Hide T and Dirks PB: Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273, 2004. (Pubitemid 39382160)
20. Nakano I and Kornblum HI: Methods for analysis of brain tumor stem cell and neural stem cell self-renewal. Methods Mol Biol 568: 37-56, 2009.
21. Kamesaki S, Kamesaki H, Jorgensen TJ, et al: bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256, 1993. (Pubitemid 24146774)
22. Kitada S, Pedersen IM, Schimmer AD and Reed JC: Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21: 3459-3474, 2002. (Pubitemid 34587716)
23. Lin H: The stem-cell niche theory: lessons from flies. Nat Rev Genet 3: 931-940, 2002.
24. Piccirillo SG, Reynolds BA, Zanetti N, et al: Bone morpho- genetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765, 2006. (Pubitemid 44949605)
25. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007. (Pubitemid 46054518)
26. Zeppernick F, Ahmadi R, Campos B, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129, 2008. (Pubitemid 351377986)
27. Curman D, Cinel B, Williams DE, et al: Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 276: 17914-17919, 2001.
28. Lomonaco SL, Finniss S, Xiang C, et al: The induction of autophagy by γ-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 125: 717-722, 2009.
29. Cheng JX, Liu BL and Zhang X: How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 35: 403-408, 2009.
30. Bredel M and Zentner J: Brain-tumour drug resistance: the bare essentials. Lancet Oncol 3: 397-406, 2002. (Pubitemid 36958270)
31. Rivera AL, Pelloski CE, Gilbert MR, et al: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121, 2010.
32. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
33. Stupp R, Mason WP, Van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
34. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
35. Brandes AA, Tosoni A, Franceschi E, et al: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27: 1275-1279, 2009.